^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sigvotatug vedotin (PF-08046047)

    i
    Other names: PF-08046047, SGN-B6A, SGNB6A, SGN B6A, PF08046047, PF 08046047
    Company:
    Pfizer
    Drug class:
    Microtubule inhibitor, Integrin beta-6-targeted antibody-drug conjugate
    Related drugs:
    4d
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    sigvotatug vedotin (PF-08046047)
    7d
    Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design. (PubMed, Future Oncol)
    Approximately 714 patients will be randomized 1:1. The dual primary endpoints are progression-free survival as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; secondary endpoints include additional efficacy, safety and tolerability, pharmacokinetics, and immunogenicity endpoints.Clinical trial registration: NCT06758401 (https://clinicaltrials.gov/study/NCT06758401).
    P3 data • Journal • Tumor proportion score • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)
    1m
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Not yet recruiting, Pfizer
    New P1/2 trial
    |
    sigvotatug vedotin (PF-08046047)
    3ms
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    sigvotatug vedotin (PF-08046047)
    4ms
    Be6A Lung-01: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=703, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | N=470 --> 703
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • sigvotatug vedotin (PF-08046047)
    5ms
    SGNB6A-001: A Study of Sigvotatug Vedotin in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1006, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: May 2028 --> Mar 2029 | Trial primary completion date: Aug 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)
    5ms
    Be6A Lung-01: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=470, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • sigvotatug vedotin (PF-08046047)
    7ms
    BE6A LUNG-02: This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (clinicaltrials.gov)
    P3, N=714, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)
    8ms
    Be6A Lung-01: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=670, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Jul 2028 --> Mar 2028 | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • sigvotatug vedotin (PF-08046047)
    8ms
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting | N=12 --> 6 | Trial completion date: Oct 2025 --> Jun 2025 | Trial primary completion date: Oct 2025 --> Jun 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    sigvotatug vedotin (PF-08046047)
    8ms
    SGNB6A-001: A Study of SGN-B6A in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1006, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Nov 2026 --> Aug 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)
    10ms
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (clinicaltrials.gov)
    P3, N=714, Not yet recruiting, Pfizer | Initiation date: Jan 2025 --> May 2025
    Trial initiation date
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)